Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry

Neuroscience

Volumn 169, Issue 4, 2010, Pages 1848-1859

  Konradsson Geuken, A ^a,d   Wu, H Q ^b   Gash, C R ^a   Alexander, K S ^a   Campbell, A ^a   Sozeri, Y ^a   Pellicciari, R ^c   Schwarcz, R ^b   Bruno, J P ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Astrocytes; Microelectrode array; Schizophrenia; 7 nicotinic receptor

Indexed keywords

ALANINE DERIVATIVE; BUNGAROTOXIN RECEPTOR; GALANTAMINE; GLUTAMIC ACID; KYNURENIC ACID; KYNURENINE; S ETHYLSULFONYLBENZOYLALANINE; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CALIBRATION; CONTROLLED STUDY; ELECTROCHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

EID: 77955421801     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.05.052     Document Type: Article

References (78)

1. Alkondon M., Pereira E.F., Eisenberg H.J., Albuquerque E.X. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for the inhibition and disinhibition of neuronal networks. J Neurosci 2000, 20:66-75.
2. Barch D.M. The cognitive neuroscience of schizophrenia. Annu Rev Clin Psychol 2005, 1:321-353.
3. Barch D.M., Smith E. The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia. Biol Psychiatry 2008, 64:11-17.
4. Biton B., Bergis O.E., Galli F., Nedelec A., Lochead A.W., Jegham S., Godet D., Lanneau C., Santamaria R., Chesney F., Léonardon J., Granger P., Debono M.W., Bohme G.A., Sgard F., Besnard F., Graham D., Coste A., Oblin A., Curet O., Vigé X., Voltz C., Rouquier L., Souilhac J., Santucci V., Gueudet C., Françon D., Steinberg R., Griebel G., Oury-Donat F., George P., Avenet P., Scatton B. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 2007, 32:1-16.
5. Burmeister J.J., Gerhardt G.A. Self referencing ceramic based multisite microelectrodes for the detection and elimination of interferences from the measurement of l-glutamate and other analytes. Anal Chem 2001, 73:1037-1042.
6. Chess A.C., Bucci D.J. Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res 2006, 170:326-332.
7. Chess A.C., Simoni M.K., Alling T.E., Bucci D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007, 33:797-804.
8. Couey J.J., Meredith R.M., Spijker S., Poorthuis R.B., Smit A.B., Brussaard A.B., Mansvelder H.D. Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron 2007, 54:73-87.
9. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006, 26:365-384.
10. Csillik B., Nemcsók J., Boncz I., Knyihár-Csillik E. Nitric oxide synthase and the acetylcholine receptor in the prefrontal cortex: metasynaptic organization of the brain. Neurobiology (Bp) 1998, 6:383-404.
11. Day B.K., Pomerleau F., Burmesiter J., Huettl P., Gerhardt G.A. Microelectrode array studies of basal and potassium-evoked release of l-glutamate in the anesthetized rat brain. J Neurochem 2006, 96:1626-1635.
12. Dean B., McLeod M., Keriakous D., McKenzie J., Scarr E. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002, 7:1083-1091.
13. Del Arco A., Mora F. Glutamate-dopamine in vivo interaction in the prefrontal cortex modulates the release of dopamine and acetylcholine in the nucleus accumbens of the awake rat. J Neural Transm 2005, 112:97-109.
14. Del Arco A., Mora F. Prefrontal cortex-nucleus accumbens interaction: in vivo modulation by dopamine and glutamate in the prefrontal cortex. Pharmacol Biochem Behav 2008, 90:226-235.
15. Dickinson J.A., Kew J.N., Wonnacott S. Presynaptic α7- and β2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol 2008, 74:348-359.
16. Duffy A., Zhou P., Milner T.A., Pickel V.M. Spatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouse. Neuroscience 2009, 161:1091-1103.
17. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic acid. CNS Drugs 2009, 23:91-101.
18. Erhardt S., Schwieler L., Emanuelsson C., Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 2004, 56:255-260.
19. Freedman R., Olincy A., Buchanan R.W., Harris J.G., Johnson L., Allensworth D., Guzman-Bonila A., Clement B., Ball M., Kutnick J., Pender V., Martin L., Stevens K., Wagner B., Zerbe G., Soti F., Kem W. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008, 165:1040-1047.
20. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., Smith Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991, 56:2007-2017.
21. Gál E.M., Sherman A.D. Synthesis and metabolism of l-kynurenine in rat brain. J Neurochem 1978, 30:607-613.
22. Geerts H., Guillaumat P.O., Grantham C., Bode W., Anciaux K., Sachak S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 2005, 1033:186-193.
23. Gioanni Y., Rougeot C., Clarke P.B.S., Lepousé C., Thierry M., Vidal C. Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur J Neurosci 1999, 11:18-30.
24. Guan Z.Z., Zhang X., Blennow K., Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 1999, 10:1779-1782.
25. Guidetti P., Amori L., Sapko M.T., Okuno E., Schwarcz R. Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem 2007, 102:103-111.
26. Guidetti P., Hoffman G.E., Melendez-Ferro M., Albuquerque E.X., Schwarcz R. Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia 2007, 55:78-92.
27. Hilmas C., Pereira E.F.R., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001, 21:7463-7473.
28. Hyde T.M., Crook J.M. Cholinergic systems and schizophrenia: primary pathology or epiphenomena?. J Chem Neuroanat 2001, 22:53-63.
29. Kessler M., Terramani T., Lynch G., Baudry M. A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 1989, 52:1319-1328.
30. Kiss C., Ceresoli-Borroni G., Guidetti P., Zielke C.L., Zielke H.R., Schwarcz R. Kynurenate production by cultured human astrocytes. J Neural Transm 2003, 110:1-14.
31. Konradsson-Geuken A., Gash C.R., Alexander K., Pomerleau F., Huettl P., Gerhardt G.A., Bruno J.P. Second-by-second analysis of alpha7 nicotine receptor regulation of glutamate release in the prefrontal cortex of awake rats. Synapse 2009, 63:1069-1082.
32. Krenz I., Kalkan D., Wevers A., de Vos R.A., Steur E.N., Lindstrom J., Pilz K., Nowacki S., Schutz U., Moser N., Witter B., Schröder H. Parvalbumin-containing interneurons of the human cerebral cortex express nicotinic acetylcholine receptor proteins. J Chem Neuroanat 2001, 21:239-246.
33. Krystal J.H. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003, 169:215-233.
34. Lambe E.K., Picciotto M.R., Aghajanian G.K. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 2003, 28:216-225.
35. Leeson V.C., Robbins T.W., Matheson E., Hutton S.B., Ron M.A., Barnes T.R., Joyce E.M. Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndrome. Biol Psychiatry 2009, 66:586-593.
36. Lewis D.A., Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 2006, 63:1372-1376.
37. Livingstone P.D., Dickinson J.A., Srinivasan J., Kew J.N., Wonnacott S. Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by alpha7 nicotinic receptors and potentiated by PNU-120596. J Mol Neurosci 2010, 40:172-176.
38. Lopes C., Pereira E.F.R., Wu H.-Q., Purushottamachar P., Njar V., Schwarcz R., Albuquerque E.X. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at α7* nicotinic receptors. J Pharmacol Exp Ther 2007, 322:48-58.
39. Marchi M., Risso F., Viola C., Cavazzani P., Raiteri M. Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 2002, 80:1071-1078.
40. Mathew S.V., Law A.J., Lipska B.K., Dávila-García M.I., Zamora E.D., Mitkus S.N., Vakkalanka R., Straub R.E., Weinberger D.R., Kleinman J.E., Hyde T.M. Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Hum Mol Genet 2007, 16:2921-2932.
41. Mexal S., Berger R., Logel J., Ross R.G., Freedman R., Leonard S. Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci 2010, 40:185-195.
42. Mitchell K.M. Acetylcholine and choline amperometric enzyme sensors characterized in vitro and in vivo. Anal Chem 2004, 76:1098-1106.
43. Nuechterlein K.H., Luck S.J., Lustig C., Sarter M. CNTRICS final task selection: control of attention. Schizophr Bull 2009, 35:182-196.
44. Parikh V., Man K., Decker M.W., Sarter M. Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J Neurosci 2008, 28:3769-3780.
45. Patti L., Raiteri L., Grilli M., Zappettini S., Bonanno G., Marchi M. Evidence that α7 nicotinic receptor modulates glutamate release from mouse neocortical gliosomes. Neurochem Int 2007, 51:1-7.
46. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1985, Academic Press, New York, NY.
47. Pellicciari R., Rizzo R.C., Costantino G., Marinozzi M., Amori L., Guidetti P., Wu H.Q., Schwarcz R. Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of S-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. Chem Med Chem 2006, 1:528-531.
48. Perkins M.N., Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 1982, 247:184-187.
49. Potter M.C., Elmer G.I., Bergeron R., Albuquerque E.X., Guidetti P., Wu H.-Q., Schwarcz R. Reduction of endogenous kynurenate formation enhances extracellular glutamate, hippocampal plasticity and cognitive behavior. Neuropsychopharmacology 2010, 35:1734-1742.
50. Quarta D., Ferré S., Solinas M., You Z.B., Hockemeyer J., Popoli P., Goldberg S.R. Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem 2004, 88:1151-1158.
51. Rassoulpour A., Wu H.Q., Ferré S., Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem 2005, 93:762-765.
52. Rassoulpour A., Guidetti P., Conley R.R., Roberts R.C., Schwarcz R. Kynurenine pathway metabolism in the neostriatum of individuals with schizophrenia. Soc Neurosci Abstr 2006, 32:588.11.
53. Robbins T.W., Murphy E.R. Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci 2006, 27:141-148.
54. Rousseau S.J., Jones W.W., Pullar I.A., Wonnacott S. Presynaptic α7 and non-α7 nicotinic acetylcholine receptors modulate [3H]D-aspartate release from rat frontal cortex in vitro. Neuropharmacology 2005, 49:59-72.
55. Rutherford E.C., Pomerleau F., Huettl P., Strömberg I., Gerhardt G.A. Chronic second-by-second measures of l-glutamate in the central nervous system of freely moving rats. J Neurochem 2007, 102:712-722.
56. Samochocki M., Höffle A., Fehrenbacher A., Jostock R., Ludwig J., Christner C., Radina M., Zerlin M., Ullmer C., Pereira E.F., Lübbert H., Albuquerque E.X., Maelicke A. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003, 305:1024-1036.
57. Sarter M., Nelson C.L., Bruno J.P. Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull 2005, 31:117-138.
58. Scarr E., Cowie T.F., Kanellakis S., Sundram S., Pantelis C., Dean B. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 2009, 14:1017-1023.
59. Schubert M.H., Young K.A., Hicks P.B. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 2006, 60:530-533.
60. Schwarcz R., Rassoulpour A., Wu H.-Q., Medoff D., Tamminga C.A., Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001, 50:521-530.
61. Shepard P.D., Joy B., Clerkin L., Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 2003, 28:1454-1462.
62. Speciale C., Wu H.Q., Gramsbergen J.B., Turski W.A., Ungerstedt U., Schwarcz R. Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: effect of aminooxyacetic acid. Neurosci Lett 1990, 116:198-203.
63. Stone T.W. Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats. Eur J Neurosci 2007, 25:2656-2665.
64. Swartz K.J., During M.J., Freese A., Beal M.F. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci 1990, 10:2965-2973.
65. Tan H.Y., Callicott J.H., Weinberger D.R. Dysfunctional and compensatory prefrontal cortical systems, genes, and the pathogenesis of schizophrenia. Cereb Cortex 2007, 17(Suppl 1):171-181.
66. Thomsen M.S., Hansen H.H., Timmerman D.B., Mikkelsen J.D. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 2010, 16:323-343.
67. Toth E., Vizi E.S., Lajtha A. Effect of nicotine on levels of extracellular amino acids in regions of the rat brain in vivo. Neuropharmacology 1993, 32:827-832.
68. Turski W.A., Gramsbergen J.B.P., Traitler H., Schwarcz R. Rat brain slices produce and liberate kynurenic acid upon exposure to l-kynurenine. J Neurochem 1989, 52:1629-1636.
69. Van der Zeyden M., Oldenziel W.H., Rea K., Cremers T.I., Westerink B.H. Microdialysis of GABA and glutamate: analysis, interpretation and comparison with microsensors. Pharmacol Biochem Behav 2008, 90:135-147.
70. Vasey M.W., Thayer J.F. The continuing problem of false positives in repeated measures ANOVA in psychophysiology: a multivariate solution. Psychophysiology 1987, 24:479-486.
71. Vidal C., Changeux J.P. Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro. Neuroscience 1993, 56:23-32.
72. Volk D.W., Lewis D.A. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav 2002, 77:501-505.
73. 2+/calmodulin signaling pathway in rat prefrontal cortex nerve terminals. Synapse 2006, 59:491-501.
74. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull 2010, 36:211-218.
75. Wu H.Q., Pellicciari R., Schwarcz R. Bidirectional regulation of extracellular dopamine by endogenous kynurenic acid in the rat medial prefrontal cortex. Soc Neurosci Abstr 2006, 32:624.3.
76. Wu H.Q., Pereira E.F.R., Bruno J.P., Pellicciari R., Albuquerque E.X., Schwarcz R. The astrocyte-derived α7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci 2010, 40:204-210.
77. Yu P., Di Prospero N.A., Sapko M.T., Cai T., Chen A., Melendez-Ferro M., Du F., Whetsell W.O., Guidetti P., Schwarcz R., Tagle D.A. Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Mol Cell Biol 2004, 24:6919-6930.
78. Zmarowski A., Wu H.Q., Brooks J.M., Potter M.C., Pellicciari R., Schwarcz R., Bruno J.P. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci 2009, 29:529-538.